3 results
Approved WMOCompleted
The primary safety endpoint is to evaluate a 30-day major adverse event (MAE) rate, where MAE is a composite of the following device- or procedure-related events: * All-cause mortality* Stroke* Life-threatening bleeding (MVARC scale)* Major vascular…
Approved WMOCompleted
The hypothesis is that SMBG underestimates the number of hyperglycaemic episodes in women with gestational diabetes mellitus. The aim of this study is to evaluate if CGMS detects hyperglycaemia when the standard SMBG day curve is normal.
Approved WMORecruiting
To assesses the efficacy of Tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1.